tiprankstipranks
Trending News
More News >

TuHURA Biosciences initiated with a Buy at Brookline

Brookline initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $9 price target TuHURA Biosciences is advancing innate immune agonists, checkpoint inhibitors, and antibody-drug conjugates to overcome checkpoint inhibitor resistance and to modulate tumor microenvironment, the analyst tells investors in a research note. The firm sees a favorable risk-reward as IFx-2.0 advances through the clinic, saying there is a significant unmet need for treatments to overcome CPI resistance in Merkel cell carcinoma.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1